Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Puma Biotechnology Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Puma Biotechnology yıllık ortalama 58.9% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19.7% annual. Gelirler declining yılda ortalama 3.9% oranında artmaktadır. Puma Biotechnology'in özkaynak karlılığı 18% ve net marjı 4%'dir.

Anahtar bilgiler

58.9%

Kazanç büyüme oranı

59.5%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	-3.9%
Özkaynak getirisi	18.0%
Net Marj	4.0%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09

Recent updates

Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Sep 07

Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

Aug 15

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Jun 07

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Jun 05

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

May 05

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Apr 10

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Mar 01

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Dec 27

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Sep 08

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Apr 17

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Dec 14

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Sep 20

Gelir ve Gider Dağılımı

Puma Biotechnology nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:PBYI Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	219	9	89	52
31 Mar 24	227	15	89	51
31 Dec 23	236	22	89	50
30 Sep 23	229	4	95	51
30 Jun 23	230	-2	98	51
31 Mar 23	235	5	94	50
31 Dec 22	228	0	92	52
30 Sep 22	218	10	87	53
30 Jun 22	207	-34	90	60
31 Mar 22	201	-49	108	67
31 Dec 21	253	-29	116	72
30 Sep 21	250	-48	122	82
30 Jun 21	255	-35	126	86
31 Mar 21	272	-27	116	92
31 Dec 20	225	-60	118	98
30 Sep 20	235	-56	120	104
30 Jun 20	241	-42	122	110
31 Mar 20	224	-82	126	123
31 Dec 19	272	-76	140	133
30 Sep 19	280	-95	151	141
30 Jun 19	287	-92	148	147
31 Mar 19	284	-99	155	154
31 Dec 18	251	-114	146	165
30 Sep 18	202	-147	136	177
30 Jun 18	145	-210	140	190
31 Mar 18	94	-243	125	200
31 Dec 17	28	-292	107	208
30 Sep 17	6	-301	92	214
30 Jun 17	0	-289	74	216
31 Mar 17	0	-278	61	217
31 Dec 16	0	-276	54	223
30 Sep 16	0	-265	47	219
30 Jun 16	0	-260	42	219
31 Mar 16	0	-258	35	224
31 Dec 15	0	-239	32	208
30 Sep 15	0	-225	30	196
30 Jun 15	0	-200	25	176
31 Mar 15	0	-175	24	151
31 Dec 14	0	-142	19	123
30 Sep 14	0	-110	14	96
30 Jun 14	0	-89	13	76
31 Mar 14	0	-63	11	52

Kaliteli Kazançlar: PBYI yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: PBYI geçmişte karlı hale geldi.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: PBYI son 5 yılda karlı hale geldi ve kazançlarını yıllık 58.9% oranında artırdı.

Büyüme Hızlandırma: PBYI son bir yılda karlı hale geldi, bu da kazanç büyüme oranının 5 yıllık ortalamayla karşılaştırılmasını zorlaştırıyor.

Kazançlar vs. Sektör: PBYI son bir yılda karlı hale geldi ve bu durum, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 0.5% ) karşılaştırılmasını zorlaştırıyor.

Özkaynak Getirisi

Yüksek ROE: PBYI 'nin Özsermaye Getirisi ( 18% ) düşük olarak değerlendiriliyor.

Puma Biotechnology Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc. to Report Q2, 2024 Results on Aug 01, 2024

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Puma Biotechnology, Inc. to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings: EPS misses analyst expectations

Recent updates

Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Independent Director recently sold US$81k worth of stock

Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

Investor sentiment deteriorates as stock falls 27%

Independent Director notifies of intention to sell stock

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Puma Biotechnology, Inc. Provides Earning Guidance for the Third Quarter and Full Year of 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Founder recently sold US$81k worth of stock

Founder notifies of intention to sell stock

Puma Biotechnology, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Investor sentiment improves as stock rises 22%

Founder notifies of intention to sell stock

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Puma Biotechnology, Inc. Announces Presentation of Findings from A Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (Tbcrc 041)

Investor sentiment deteriorates as stock falls 20%

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Puma Biotechnology, Inc., Annual General Meeting, Jun 18, 2024

Puma Biotechnology, Inc. to Report Q1, 2024 Results on May 02, 2024

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Investor sentiment deteriorates as stock falls 15%

Consensus EPS estimates increase by 45%, revenue downgraded

New minor risk - Shareholder dilution

Full year 2023 earnings: EPS misses analyst expectations

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Puma Biotechnology, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Puma Biotechnology, Inc. Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

Investor sentiment improves as stock rises 22%

New minor risk - Share price stability

Founder notifies of intention to sell stock

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Puma Biotechnology, Inc. Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Investor sentiment improves as stock rises 15%

Independent Director recently sold US$71k worth of stock

Independent Director notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

New major risk - Financial position

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Puma Biotechnology, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Puma Biotechnology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Puma Biotechnology, Inc. Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Puma Biotechnology, Inc. Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer

New major risk - Revenue and earnings growth

Puma Biotechnology, Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Founder notifies of intention to sell stock

Puma Biotechnology, Inc. Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel Versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 32%, revenue downgraded

Investor sentiment improves as stock rises 17%

Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Consensus EPS estimates increase by 240%

Full year 2022 earnings released: EPS: US$0 (vs US$0.72 loss in FY 2021)

Puma Biotechnology, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Puma Biotechnology, Inc.’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Breast Cancer with a HER2 Mutation

Founder recently sold US$114k worth of stock

Founder notifies of intention to sell stock